PRI-002, Oral Therapy Candidate for Alzheimer’s, Deemed Safe in Phase 1 Trial

PRI-002, Oral Therapy Candidate for Alzheimer’s, Deemed Safe in Phase 1 Trial
Alzheimer's oral therapy candidate PRI-002, being developed by Priavoid, has proven safe for human use in healthy volunteers during a Phase 1 clinical trial. These positive trial results provide important evidence that supports progressing PRI-002 into studies of patients who have Alzheimer's disease. "Our next goal is the proof of efficacy in patients," Dieter Willbold, PhD, director of Jülich’s Structural Biochemistry Institute (ICS-6), and one of the inventors of PRI-002, said in a press release. "We hope to successfully take this path with the company Priavoid." The trial (NCT03944460) investigated the safety, tolerability, and availability and metabolism in the body of five different doses — 4, 12, 36, 108, and 320 mg capsules — of PRI-002 administered just one time. A total of 40 healthy male volunteers were enrolled in the study, 10 of whom received an equivalent dose of placebo. In a previous analysis, the investigational therapy proved safe at its highest dose,
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *